BelCoPhar SRL
BelCoPhar reported total assets of 224,468 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Sep 2026).
The score of BelCoPhar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity +95 % Total assets +64 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
BelCoPhar's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Sep 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 21 Oct 2024
BelCoPhar's financial analysis
- Solvency78.6%sector median: 47.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of BelCoPhar
BelCoPhar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0789.518.434
- VAT number
- BE0789518434
- Peppol
- Registered · 0208:0789518434 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 09 Aug 2022
- Registered office
- 2920 Kalmthout
- Latest accounts
- 2025 · filed on 30 Sep 2026
- Activity
- Manufacture of medicaments (NACE 21201)
BelCoPhar (SRL) has been based in Kalmthout since 2022, active in: manufacture of medicaments. For 2025, it reports a net profit of 28,535 € and equity of 176,428 €; its revenue is not published. Its solvency stands at 78.6%, above the median of its sector (47.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to BelCoPhar
Companies in the same business, of comparable size and area, outside its group.
- Mayaku Pharmaceutical Development Manufacture of basic pharmaceutical products Ghent · balance sheet 170,483 €
- L - Pharma Manufacture of pharmaceutical preparations Turnhout · balance sheet 10 €
- RTLC Manufacture of pharmaceutical preparations Brussels · balance sheet 107,167 €
- Montefalcone Projects Manufacture of basic pharmaceutical products Maarkedal · balance sheet 207,746 €
- Wandji Pharma International Manufacture of pharmaceutical preparations Tournai · balance sheet 357,118 €
- Oropharma Manufacture of pharmaceutical preparations Deinze · balance sheet 352,437 €
- Medipharm Worldwide Group Manufacture of basic pharmaceutical products Tienen · balance sheet 331,081 €
- Pharmacie Courouble Manufacture of basic pharmaceutical products Schaerbeek · balance sheet 129,672 €
Frequently asked questions about BelCoPhar
What is the revenue of BelCoPhar?
BelCoPhar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of BelCoPhar?
In Belgium, the VAT number is the company number prefixed with BE: BE0789518434 for BelCoPhar, if the company is VAT-registered. Its company number (CBE) is 0789.518.434.
Where is the registered office of BelCoPhar?
According to the CBE register, the registered office of BelCoPhar is in 2920 Kalmthout.
What is the equity of BelCoPhar?
At the close of the 2025 financial year, the equity of BelCoPhar amounts to 176,428 €, a solvency of 78.6% of total assets.
Who manages BelCoPhar?
The register lists 3 active mandates at BelCoPhar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of BelCoPhar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →